首頁 > 市場調查報告書 > 製藥

生物製劑分子標靶治療學

抗體片段市場規模、佔有率和成長分析（按特異性、片段類型、應用、最終用途和地區分類）－2025-2032年產業預測

市場調查報告書

商品編碼

1865325

抗體片段市場規模、佔有率和成長分析（按特異性、片段類型、應用、最終用途和地區分類）－2025-2032年產業預測

Antibody Fragments Market Size, Share, and Growth Analysis, By Specificity (Monoclonal Antibody Fragments, Polyclonal Antibody Fragments), By Fragment Type, By Application, By End Use, By Region - Industry Forecast 2025-2032

出版日期: 2025年11月04日 | 出版商:

SkyQuest | 英文 180 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

預計到 2023 年，全球抗體片段市場規模將達到 72 億美元，到 2024 年將達到 76.2 億美元，到 2032 年將達到 119.6 億美元，預測期（2025-2032 年）的複合年成長率為 5.8%。

在對標靶高效治療方法和診斷方法日益成長的需求推動下，抗體片段市場正迅速崛起，成為生物學領域的重要組成部分。這些片段以多種形式存在，例如Fab片段、單鏈可變區片段（scFv）和奈米抗體，與傳統單株抗體相比具有顯著優勢。蛋白質工程、展示技術和計算設計的進步提高了這些片段的穩定性、結合能力和可生產性。隨著對創新治療方法的需求不斷成長，抗體片段作為雙特異性抗體、抗體藥物複合體（CAR）構建體，尤其是在腫瘤學和罕見疾病領域，正日益受到重視。其快速清除和特異性也使其在診斷、影像和個人化醫療等領域具有應用前景，進一步推動了市場擴張。

全球抗體片段市場促進因素

全球抗體片段市場的主要促進因素之一是針對包括癌症和自體免疫免疫疾病在內的各種疾病的標靶治療需求不斷成長。對癌症生物學認知的不斷深入推動了對更精準、更有效治療方法的需求，進而引發了人們對單鏈可變區片段（scFv）和雙特異性抗體等抗體片段的濃厚興趣。與全長抗體相比，這些片段具有許多優勢，例如體積較小、組織滲透性較強、免疫抗原性較低。此外，它們在藥物研發中的多功能性以及聯合治療的潛力也是推動市場擴張的重要因素。

限制全球抗體片段市場的因素

全球抗體片段市場的主要限制因素之一是此類特殊療法研發成本高成本。抗體設計的複雜性以及臨床試驗嚴格的監管要求需要大量資金投入，這可能會限制中小型生物技術公司的進入，並扼殺創新。此外，成熟製藥公司擁有強大的研發管線，競爭格局也對尋求市場佔有率的新參與企業構成挑戰。這些因素可能會阻礙市場成長，降低抗體片段療法的整體可及性，從而威脅到標靶治療的發展。

全球抗體片段市場趨勢

全球抗體片段市場正經歷顯著成長，尤其是在腫瘤學和診斷領域。這一趨勢主要得益於抗體片段的日益普及。抗體片段具有優異的腫瘤穿透性和快速的循環清除特性，使其成為放射性標記後造影劑和標靶治療的理想選擇。基於片段的偶聯物和雙特異性抗體正受到越來越多的關注，研究人員和開發人員致力於利用模組化設計來提高治療效果，同時最大限度地減少脫靶效應。這種創新方法不僅提高了癌症治療的精準度，也促進了抗體片段在各種治療和診斷應用中的進一步探索，從而推動了市場擴張。

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 亞太其他地區
拉丁美洲
- 巴西
- 其他拉丁美洲地區
中東和非洲
- 海灣合作理事會國家
- 南非
- 其他中東和非洲地區

競爭資訊

前五大公司對比
主要企業的市場定位（2024 年）
主要市場參與者所採取的策略
近期市場趨勢
公司市佔率分析（2024 年）
主要企業公司簡介
- 公司詳情
- 產品系列分析
- 依業務板塊進行公司股票分析
- 2022-2024年營收年比比較

主要企業簡介

Pfizer Inc.
Novartis AG
Roche Holding AG
AbbVie Inc.
Bristol-Myers Squibb Company
Johnson & Johnson
Amgen Inc.
Merck KGaA
Genentech, Inc.
Ablynx（Sanofi）
Eli Lilly and Company
Akeso, Inc.
Taisho Pharmaceutical Co., Ltd.
MacroGenics, Inc.
Harpoon Therapeutics, Inc.
Chengdu Huasun Technology Group Inc.
Thermo Fisher Scientific Inc.
Sartorius AG
Abcam plc
Genscript Biotech Corporation

結論與建議

簡介目錄

Product Code: SQMIG35B2263

Global Antibody Fragments Market size was valued at USD 7.2 billion in 2023 and is poised to grow from USD 7.62 billion in 2024 to USD 11.96 billion by 2032, growing at a CAGR of 5.8% during the forecast period (2025-2032).

The antibody fragments market is emerging as a vital segment within the broader biological arena, fueled by the rising need for targeted and efficient therapeutics and diagnostics. With various formats such as Fab fragments, single-chain variable fragments (scFv), and nanobodies, these fragments offer substantial benefits over traditional monoclonal antibodies. Advances in protein engineering, display technologies, and computational design are enhancing the stability, binding, and manufacturability of these fragments. As demand for innovative therapeutic options grows, antibody fragments are increasingly recognized as foundational elements for bispecifics, antibody-drug conjugates (ADCs), and CAR constructs, particularly in oncology and rare diseases. Their rapid clearance and specificity also make them suitable for diagnostics, imaging, and personalized medicine, further driving market expansion.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Antibody Fragments market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Antibody Fragments Market Segments Analysis

Global Antibody Fragments Market is segmented by Specificity, Fragment Type, Application, End Use and region. Based on Specificity, the market is segmented into Monoclonal Antibody Fragments and Polyclonal Antibody Fragments. Based on Fragment Type, the market is segmented into Fab Fragments, scFv (Single-Chain Variable Fragments), sdAb (Single-Domain Antibodies / Nanobodies) and Others. Based on Application, the market is segmented into Therapeutics, Diagnostics and Research Tools & Kits. Based on End Use, the market is segmented into Oncology, Immunology / Autoimmune Diseases, Infectious Diseases and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Antibody Fragments Market

One key market driver for the global antibody fragments market is the increasing demand for targeted therapies in the treatment of various diseases, including cancer and autoimmune disorders. As the understanding of cancer biology advances, the desire for more precise and effective treatments has led to a surge in interest in antibody fragments, such as single-chain variable fragments (scFvs) and bispecific antibodies. These fragments offer advantages like smaller size, enhanced tissue penetration, and reduced immunogenicity compared to full-length antibodies. Furthermore, their versatility in drug development and potential for combination therapies contribute significantly to the expanding market landscape.

Restraints in the Global Antibody Fragments Market

One of the key market restraints for the global antibody fragments market is the high cost associated with the research and development of these specialized therapeutics. The complexity of antibody engineering and the stringent regulatory requirements for clinical trials necessitate significant financial investment, which can limit the entry of smaller biotech firms and restrict innovation. Additionally, the competitive landscape, featuring established pharmaceutical companies with robust pipelines, poses challenges for new entrants seeking market share. These factors can impede growth and reduce the overall accessibility of antibody fragment-based therapies, hindering advancements in targeted treatment options.

Market Trends of the Global Antibody Fragments Market

The Global Antibody Fragments market is experiencing significant growth, particularly within the oncology and diagnostics sectors. This trend is fueled by the rising adoption of antibody fragments, which offer superior tumor penetration and rapid circulation clearance, making them ideal for both imaging agents and targeted therapies when radiolabeled. The focus on fragment-based conjugates and bispecific antibodies is intensifying, as researchers and developers aim to enhance therapeutic efficacy while minimizing off-target effects through modularity. This innovative approach not only enhances the precision of cancer treatments but also prompts further exploration of antibody fragments in various therapeutic and diagnostic applications, driving market expansion.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2024
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Technology Assessment
Regulatory Landscape

Global Antibody Fragments Market Size by Specificity & CAGR (2025-2032)

Market Overview
Monoclonal Antibody Fragments
Polyclonal Antibody Fragments

Global Antibody Fragments Market Size by Fragment Type & CAGR (2025-2032)

Market Overview
Fab Fragments
scFv (Single-Chain Variable Fragments)
sdAb (Single-Domain Antibodies / Nanobodies)
Others

Global Antibody Fragments Market Size by Application & CAGR (2025-2032)

Market Overview
Therapeutics
Diagnostics
Research Tools & Kits

Global Antibody Fragments Market Size by End Use & CAGR (2025-2032)

Market Overview
Oncology
Immunology / Autoimmune Diseases
Infectious Diseases
Others

Global Antibody Fragments Market Size & CAGR (2025-2032)

North America (Specificity, Fragment Type, Application, End Use)
- US
- Canada
Europe (Specificity, Fragment Type, Application, End Use)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Specificity, Fragment Type, Application, End Use)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Specificity, Fragment Type, Application, End Use)
- Brazil
- Rest of Latin America
Middle East & Africa (Specificity, Fragment Type, Application, End Use)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2024
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2024
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

Pfizer Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Roche Holding AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AbbVie Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bristol-Myers Squibb Company
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Amgen Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck KGaA
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Genentech, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Ablynx (Sanofi)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eli Lilly and Company
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Akeso, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Taisho Pharmaceutical Co., Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
MacroGenics, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Harpoon Therapeutics, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Chengdu Huasun Technology Group Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Thermo Fisher Scientific Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sartorius AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Abcam plc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Genscript Biotech Corporation
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments